

## Clinical trial information

Registration Item	Details of registration Item	Contents
Title of the study	Title of the study	Phase IIa study of T-5224 in RA patients
	Primary sponsor	Toyama Chemical Co., Ltd
	Study Type	interventional (treatment)
	Summary	To evaluate the efficacy and safety of T-5224 at 12 weeks administration in RA patients.
Details of study	Interventional drug name	T-5224
	Target illness	Rheumatoid Arthritis
	Classification name (code) of the investigational drug	399
	Administration route	Oral administration
	Control drug name(code/td)	Placebo
	Classification name (code) of the investigational drug	---
	Administration route	Oral administration
	Objectives of the study	Medical treatment
	Study phase	Phase II
	Study design	Double blind, randomized and multi center
	Inclusion Criteria Exclusion Criteria	<p>Inclusion Criteria</p> <ul style="list-style-type: none"> <li>• Male or female.</li> <li>• Subject who have a diagnosis of Rheumatoid Arthritis by the ACR criteria.</li> <li>• Age greater or 20 years and less than 65 years old.</li> <li>• Subject who diagnosed to class 1-3 of Steinblocker dysfunction classification.</li> </ul> <p>Exclusion Criteria</p> <ul style="list-style-type: none"> <li>• Subject with autoimmune disease except RA and SS.</li> <li>• Subject who is pregnancy, has possibility of pregnancy, hopes for pregnancy, is suckling.</li> </ul>
	Outcome	Efficacy and safety
	Study status	On going
	Duration of the study	From November 1 2010 to May 31 2012
Region	Japan	
Contact information	Organization	Toyama Chemical Co., Ltd.
	Division	Clinical Planning Department
	Inquiries	Form for Inquiry <a href="https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn">https://www.toyama-chemical.co.jp/en/form/general/input.php?id=TCClinicalEn</a>